Validity and reliability of the migraine-treatment optimization questionnaire

R. B. Lipton; K. Kolodner; M. E. Bigal; D. Valade; M. J.A. Láinez; J. Pascual; A. Gendolla; G. Bussone; N. Islam; K. Albert; B. Parsons

doi:10.1111/j.1468-2982.2008.01786.x

Validity and reliability of the migraine-treatment optimization questionnaire

R. B. Lipton, K. Kolodner, M. E. Bigal, D. Valade, M. J.A. Láinez, J. Pascual, A. Gendolla, G. Bussone, N. Islam, K. Albert, B. Parsons

Neurology

Research output: Contribution to journal › Article › peer-review

66 Scopus citations

Abstract

Our aim was to establish the validity and reliability of a patient-rated Migraine Treatment Optimization Questionnaire (M-TOQ) in primary care. Patients who met International Classification of Headache Disorders, 2nd edn criteria for migraine completed a 19-item questionnaire containing candidate items for the M-TOQ, and three questionnaires designed to test convergent/construct validity [Migraine Disability Assessment Scale (MIDAS), Headache Impact Test (HIT)-6 and Migraine-Specific Quality of Life Scale (MSQoL)]. A 15-item (M-TOQ-15) and a five-item (M-TOQ-5) questionnaire were derived. Two hundred and fifty-three adult patients were recruited. Five treatment optimization domains were identified: functioning, rapid relief, consistency of relief, risk of recurrence and tolerability; with Cronbach alphas of 0.70-0.84. The Cronbach α for M-TOQ-15 was 0.85, and it correlated well with MIDAS, HIT-6 and MSQoL (r = 0.33-0.44). The Cronbach α for M-TOQ-5 was 0.66, and it also correlated well with the three questionnaires (r = 0.33-0.41). The utility of the M-TOQ for assessing treatment benefit in research (M-TOQ-15) and primary care (M-TOQ-5) should be further validated.

Original language	English (US)
Pages (from-to)	751-759
Number of pages	9
Journal	Cephalalgia
Volume	29
Issue number	7
DOIs	https://doi.org/10.1111/j.1468-2982.2008.01786.x
State	Published - Jul 2009

Keywords

Migraine
Reliability
Treatment optimization
Validity

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1111/j.1468-2982.2008.01786.x

Cite this

@article{8f8057cad49a4ca0b41a4bf1c2a29cf1,

title = "Validity and reliability of the migraine-treatment optimization questionnaire",

abstract = "Our aim was to establish the validity and reliability of a patient-rated Migraine Treatment Optimization Questionnaire (M-TOQ) in primary care. Patients who met International Classification of Headache Disorders, 2nd edn criteria for migraine completed a 19-item questionnaire containing candidate items for the M-TOQ, and three questionnaires designed to test convergent/construct validity [Migraine Disability Assessment Scale (MIDAS), Headache Impact Test (HIT)-6 and Migraine-Specific Quality of Life Scale (MSQoL)]. A 15-item (M-TOQ-15) and a five-item (M-TOQ-5) questionnaire were derived. Two hundred and fifty-three adult patients were recruited. Five treatment optimization domains were identified: functioning, rapid relief, consistency of relief, risk of recurrence and tolerability; with Cronbach alphas of 0.70-0.84. The Cronbach α for M-TOQ-15 was 0.85, and it correlated well with MIDAS, HIT-6 and MSQoL (r = 0.33-0.44). The Cronbach α for M-TOQ-5 was 0.66, and it also correlated well with the three questionnaires (r = 0.33-0.41). The utility of the M-TOQ for assessing treatment benefit in research (M-TOQ-15) and primary care (M-TOQ-5) should be further validated.",

keywords = "Migraine, Reliability, Treatment optimization, Validity",

author = "Lipton, {R. B.} and K. Kolodner and Bigal, {M. E.} and D. Valade and L{\'a}inez, {M. J.A.} and J. Pascual and A. Gendolla and G. Bussone and N. Islam and K. Albert and B. Parsons",

note = "Funding Information: The authors gratefully acknowledge the assistance of the M-TOQ Investigators: Dr Edward Linkner, Dr Gary E. Leeds, Dr Steven Miller, Dr Peter Scuccimarri, Dr James Kim, Dr Janet Vickers, Dr Bastian Steinberg, Dr Gerd-Ewald von Manteuffel, Dr Sabine Strache, Dr Marianne Lang, Dr Beate M{\"o}ckesch. Dr Peter Steul, Dr Michel Dizin, Dr Florence Tiberghien Chatelain, Dr Sebastien Cornu, Dr Jean-Pierre Lacaste, Dr Salvador Tranche, Dr Jesus Castillo Obeso, Dr Silvia Copeti, Dr Vicente Baos, Dr R. Equinozzi, Dr M. Hanke, Dr Massimo Montironi, Dr A. Pieroni and Dr G. Riommi. We also thank Drs Andrew Dowson and Stewart Tepper, the developers of Migraine-ACT, for their advice in the earlier stages of this project. This study was sponsored by Pfizer Inc., but the design, conduct, data collection, analysis and interpretation were carried out by Prof. Richard Lipton and his staff. Editorial support was provided by Dr Edward Schweizer and GCL, Maidenhead, UK, and was funded by Pfizer Inc.",

year = "2009",

month = jul,

doi = "10.1111/j.1468-2982.2008.01786.x",

language = "English (US)",

volume = "29",

pages = "751--759",

journal = "Cephalalgia",

issn = "0333-1024",

publisher = "SAGE Publications Ltd",

number = "7",

}

TY - JOUR

T1 - Validity and reliability of the migraine-treatment optimization questionnaire

AU - Lipton, R. B.

AU - Kolodner, K.

AU - Bigal, M. E.

AU - Valade, D.

AU - Láinez, M. J.A.

AU - Pascual, J.

AU - Gendolla, A.

AU - Bussone, G.

AU - Islam, N.

AU - Albert, K.

AU - Parsons, B.

N1 - Funding Information: The authors gratefully acknowledge the assistance of the M-TOQ Investigators: Dr Edward Linkner, Dr Gary E. Leeds, Dr Steven Miller, Dr Peter Scuccimarri, Dr James Kim, Dr Janet Vickers, Dr Bastian Steinberg, Dr Gerd-Ewald von Manteuffel, Dr Sabine Strache, Dr Marianne Lang, Dr Beate Möckesch. Dr Peter Steul, Dr Michel Dizin, Dr Florence Tiberghien Chatelain, Dr Sebastien Cornu, Dr Jean-Pierre Lacaste, Dr Salvador Tranche, Dr Jesus Castillo Obeso, Dr Silvia Copeti, Dr Vicente Baos, Dr R. Equinozzi, Dr M. Hanke, Dr Massimo Montironi, Dr A. Pieroni and Dr G. Riommi. We also thank Drs Andrew Dowson and Stewart Tepper, the developers of Migraine-ACT, for their advice in the earlier stages of this project. This study was sponsored by Pfizer Inc., but the design, conduct, data collection, analysis and interpretation were carried out by Prof. Richard Lipton and his staff. Editorial support was provided by Dr Edward Schweizer and GCL, Maidenhead, UK, and was funded by Pfizer Inc.

PY - 2009/7

Y1 - 2009/7

N2 - Our aim was to establish the validity and reliability of a patient-rated Migraine Treatment Optimization Questionnaire (M-TOQ) in primary care. Patients who met International Classification of Headache Disorders, 2nd edn criteria for migraine completed a 19-item questionnaire containing candidate items for the M-TOQ, and three questionnaires designed to test convergent/construct validity [Migraine Disability Assessment Scale (MIDAS), Headache Impact Test (HIT)-6 and Migraine-Specific Quality of Life Scale (MSQoL)]. A 15-item (M-TOQ-15) and a five-item (M-TOQ-5) questionnaire were derived. Two hundred and fifty-three adult patients were recruited. Five treatment optimization domains were identified: functioning, rapid relief, consistency of relief, risk of recurrence and tolerability; with Cronbach alphas of 0.70-0.84. The Cronbach α for M-TOQ-15 was 0.85, and it correlated well with MIDAS, HIT-6 and MSQoL (r = 0.33-0.44). The Cronbach α for M-TOQ-5 was 0.66, and it also correlated well with the three questionnaires (r = 0.33-0.41). The utility of the M-TOQ for assessing treatment benefit in research (M-TOQ-15) and primary care (M-TOQ-5) should be further validated.

AB - Our aim was to establish the validity and reliability of a patient-rated Migraine Treatment Optimization Questionnaire (M-TOQ) in primary care. Patients who met International Classification of Headache Disorders, 2nd edn criteria for migraine completed a 19-item questionnaire containing candidate items for the M-TOQ, and three questionnaires designed to test convergent/construct validity [Migraine Disability Assessment Scale (MIDAS), Headache Impact Test (HIT)-6 and Migraine-Specific Quality of Life Scale (MSQoL)]. A 15-item (M-TOQ-15) and a five-item (M-TOQ-5) questionnaire were derived. Two hundred and fifty-three adult patients were recruited. Five treatment optimization domains were identified: functioning, rapid relief, consistency of relief, risk of recurrence and tolerability; with Cronbach alphas of 0.70-0.84. The Cronbach α for M-TOQ-15 was 0.85, and it correlated well with MIDAS, HIT-6 and MSQoL (r = 0.33-0.44). The Cronbach α for M-TOQ-5 was 0.66, and it also correlated well with the three questionnaires (r = 0.33-0.41). The utility of the M-TOQ for assessing treatment benefit in research (M-TOQ-15) and primary care (M-TOQ-5) should be further validated.

KW - Migraine

KW - Reliability

KW - Treatment optimization

KW - Validity

UR - http://www.scopus.com/inward/record.url?scp=66749156463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749156463&partnerID=8YFLogxK

U2 - 10.1111/j.1468-2982.2008.01786.x

DO - 10.1111/j.1468-2982.2008.01786.x

M3 - Article

C2 - 19239676

AN - SCOPUS:66749156463

SN - 0333-1024

VL - 29

SP - 751

EP - 759

JO - Cephalalgia

JF - Cephalalgia

IS - 7

ER -

Validity and reliability of the migraine-treatment optimization questionnaire

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this